The US Food and Drug Administration has given its approval to a new type of painkiller called Suzetrigine, sold as Journavx. This medication is administered twice daily in 50-milligram oral tablets to treat moderate and severe acute pain. Clinical trials have shown that Suzetrigine can effectively manage pain, rivaling the effects of opioid-based medications. The breakthrough lies in its lower risk of addiction, a significant concern with many existing painkillers.
Source: https://www.scientificamerican.com/article/what-is-journavx-the-new-opioid-free-painkiller-from-vertex